Total raised
$132.0M
Last: Series C 2024-07
Stage
Series C
Founded
2016
Headcount
124
HQ
-
Sector
Health Tech & Life Sciences
About
CytoReason is a technology company developing a computational model of the human body that simulates human disease on a cellular level, minimizes the need for animal trials, and makes human trials more focused and accurate.
With CytoReason's proprietary database and AI-led platform, pharmaceutical and biotechnology companies can make data-driven decisions quickly and cost effectively. To date, five of the world’s top ten pharma companies use CytoReason’s technology to identify new opportunities, shorten trial phases, reduce development costs, and increase the likelihood of drug approval.
Funding history · 6 rounds · $132.0M total
2024-07
Series C
$80.0M
2024-05
Series B
Undisclosed
2022-10
Convertible Debt
$30.0M
2021-06
Series A
$8.4M
2020-07
Series A
$10.8M
2020-01
Seed
$2.8M
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesDigital HealthcareMedical Decision Support
Technologies
BiologicalsCellsArtificial IntelligenceMachine Learning
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcareProvidersLaboratories
Business model
B2B
Highlights
Verified
Tags
clinical-trialslaboratoriesartificial-intelligencehealthcare-providerspatent-pendingdrug-discoveryclinical-dataclinicsmedical-technologiesdata-analyticsdigital-healthcarebig-datapharma-companiescancermachine-learningbiotechnologybiopharmaceuticalimmunotherapyimmunologybioinformaticsmhealthautoimmune-diseasesmolecular-biologydecision-supportnatural-language-processingcells